Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05862051Not ApplicableActive Not Recruiting

RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

Role: collaborator

NCT00096408Phase 3Completed

Laparoscopic Approach to Cancer of the Endometrium

Role: collaborator

NCT02971709Not ApplicableCompleted

Use of Shade in U.S. and Australian City Parks

Role: collaborator

NCT03227003Completed

DNA Methylation and 1-C Metabolism Nutrient Intake

Role: lead

All 4 trials loaded